AGM Statement

RNS Number : 0894E

Futura Medical PLC

07 May 2013

 



For immediate release

7 May 2013

 

 

Futura Medical PLC

("Futura" or the "Company")

AGM Statement

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will hold its Annual General Meeting in London later today.

At the meeting, John Clarke, Futura's Chairman, will make the following statement:

"The re-licensing of CSD500 on a territorial basis has been a key priority for us during the past few months. We were therefore delighted to announce last month that Church & Dwight had acquired the rights to CSD500 in North America and some European countries. Our out-licensing discussions continue for other geographies, and we look forward to announcing further deals in due course.

"We have recently submitted the CSD500 regulatory dossier for CE mark approval, which we are on track to receive in the second half of this year. I am also pleased to report that we have this month gained ISO 13485 certification as part of our preparation for becoming the regulatory licence holder of the product.

"On PET500, we continue to work closely with our marketing partner, Ansell, and we expect Ansell to carry out a soft launch of the product later this year in the US.

"The new clinical study of our cellulite reduction product, CRF100, is now fully enrolled and progressing on schedule. We expect to provide the full results of the study at the time of our interim financial results in September.

"In summary we are making excellent progress, both with CSD500 and with other products in our development portfolio."

For further information:

Futura Medical plc	+ 44 (0) 1483 685 670
James Barder, Chief Executive
Mail to: [e-mail]	www.futuramedical.com
Nomura Code Securities Limited	+ 44 (0) 20 7776 1200
Phil Walker / Giles Balleny
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare.  The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com 

 

END

 

 

AGMUBOVROOAVRRR